Bionet - Asset Resilience Ratio

Latest as of September 2025: 38.62%

Bionet (1784) has an Asset Resilience Ratio of 38.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Bionet for a breakdown of total debt and financial obligations.

Liquid Assets

NT$1.20 Billion

≈ $37.70 Million USD Cash + Short-term Investments

Total Assets

NT$3.10 Billion

≈ $97.62 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Bionet's Asset Resilience Ratio has changed over time. See Bionet (1784) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bionet's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bionet (1784) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$1.20 Billion	38.62%
Total Liquid Assets	NT$1.20 Billion	38.62%

Asset Resilience Insights

Very High Liquidity: Bionet maintains exceptional liquid asset reserves at 38.62% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Bionet Industry Peers by Asset Resilience Ratio

Compare Bionet's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	6.56%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Imagion Biosystems Ltd AU:IBX	Diagnostics & Research	150.16%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Bionet (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Bionet.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	42.27%	NT$1.33 Billion ≈ $42.03 Million	NT$3.16 Billion ≈ $99.44 Million	+13.79pp
2023-12-31	28.48%	NT$668.86 Million ≈ $21.07 Million	NT$2.35 Billion ≈ $74.00 Million	+13.40pp
2022-12-31	15.08%	NT$277.20 Million ≈ $8.73 Million	NT$1.84 Billion ≈ $57.93 Million	+0.32pp
2021-12-31	14.76%	NT$263.29 Million ≈ $8.30 Million	NT$1.78 Billion ≈ $56.20 Million	-0.32pp
2020-12-31	15.08%	NT$261.59 Million ≈ $8.24 Million	NT$1.73 Billion ≈ $54.65 Million	-3.08pp
2019-12-31	18.16%	NT$319.78 Million ≈ $10.07 Million	NT$1.76 Billion ≈ $55.49 Million	+0.20pp
2018-12-31	17.96%	NT$320.20 Million ≈ $10.09 Million	NT$1.78 Billion ≈ $56.18 Million	-2.12pp
2017-12-31	20.08%	NT$366.44 Million ≈ $11.54 Million	NT$1.82 Billion ≈ $57.50 Million	--

pp = percentage points

About Bionet

TWO:1784 Taiwan Diagnostics & Research

Market Cap

$119.66 Million

NT$3.80 Billion TWD

Market Cap Rank

#18502 Global

#1005 in Taiwan

Share Price

NT$75.50

Change (1 day)

-0.26%

52-Week Range

NT$64.60 - NT$115.50

All Time High

NT$161.50